Korean J Gastroenterol.  2020 Nov;76(5):261-264. 10.4166/kjg.2020.121.

Oxaliplatin-induced Sudden Hearing Loss in a Patient with Pancreatic Cancer

• Kim SB
• Kim SY
• Kim KH
• Kim TN

• KMID: 2508877
• DOI: http://doi.org/10.4166/kjg.2020.121

Abstract

Oxaliplatin is a new generation of platinum derivatives used frequently to treat solid organ malignancies, including colorectal and ovarian cancer. Recently, an oxaliplatin-based chemotherapeutic regimen was adopted for advanced pancreatic cancer. Although oxaliplatin has extensive therapeutic potential, its use can be limited by significant adverse effects, particularly ototoxicity. This paper reports a rare case of irreversible unilateral hearing loss in a 48-year-old female that developed after the intravenous infusion of oxaliplatin during pancreatic cancer treatment. To the best of the authors’ knowledge, this is the second reported case of oxaliplatin-related ototoxicity in pancreatic cancer.

Keyword

Ototoxicity; Oxaliplatin; Chemotherapy; Pancreatic neoplasms

Figure

• 

  Fig. 1 After 13 days from 6th cycle of a FOLFIRINOX regimen, audiometry revealed severe to profound hearing loss of the left ear.

Reference

1. Hijri FZ, Arifi S, Ouattassi N, Mellas N, El Mesbahi O. 2014; Oxaliplatin-induced ototoxicity in adjuvant setting for colorectal cancer: unusual side effect. J Gastrointest Cancer. 45:106–108. DOI: 10.1007/s12029-013-9489-3. PMID: 23494572.

2. Piccart MJ, Lamb H, Vermorken JB. 2001; Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol. 12:1195–1203. DOI: 10.1023/A:1012259625746. PMID: 11697824.

3. Malhotra NK, Aslam R, Lipman SP, Bilski VJ. 2010; Acute ototoxicity from a single infusion of oxaliplatin. Ear Nose Throat J. 89:258–261. DOI: 10.1177/014556131008900607. PMID: 20556736.

4. Oh SY, Wasif N, Garcon MC, Rodriguez G, Saif MW. 2013; Ototoxicity associated with oxaliplatin in a patient with pancreatic cancer. JOP. 14:676–679. DOI: 10.6092/1590-8577/1629. PMID: 24216561.

5. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. 2004; FDA drug approval summaries: oxaliplatin. Oncologist. 9:8–12. DOI: 10.1634/theoncologist.9-1-8. PMID: 14755010.

6. Raymond E, Chaney SG, Taamma A, Cvitkovic E. 1998; Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 9:1053–1071. DOI: 10.1023/A:1008213732429. PMID: 9834817.

7. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. 2003; Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs. 63:1549–1563. DOI: 10.2165/00003495-200363150-00003. PMID: 12887262.

8. Hoff PM, Saad ED, Costa F, et al. 2012; Literature review and practical aspects on the management of oxaliplatin-associated toxicity. Clin Colorectal Cancer. 11:93–100. DOI: 10.1016/j.clcc.2011.10.004. PMID: 22154408.

9. Rybak LP, Whitworth CA, Mukherjea D, Ramkumar V. 2007; Mechanisms of cisplatin-induced ototoxicity and prevention. Hear Res. 226:157–167. DOI: 10.1016/j.heares.2006.09.015. PMID: 17113254.

10. Hellberg V, Wallin I, Eriksson S, et al. 2009; Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst. 101:37–47. DOI: 10.1093/jnci/djn418. PMID: 19116379. PMCID: PMC2639295.

11. Ding D, Allman BL, Salvi R. 2012; Review: ototoxic characteristics of platinum antitumor drugs. Anat Rec (Hoboken). 295:1851–1867. DOI: 10.1002/ar.22577. PMID: 23044998.

12. Güvenç MG, Dizdar D, Dizdar SK, Okutur SK, Demir G. 2016; Sudden hearing loss due to oxaliplatin use in a patient with colon cancer. J Chemother. 28:341–342. DOI: 10.1179/1973947815Y.0000000023. PMID: 25872564.

13. Vietor NO, George BJ. 2012; Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent. J Oncol Pharm Pract. 18:355–359. DOI: 10.1177/1078155212437901. PMID: 22333669.